NKGNNKGen Biotech, Inc.

Nasdaq nkgenbiotech.com


$ 0.77 $ 0.03 (3.36 %)    

Monday, 09-Sep-2024 15:59:08 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 0.809
$ 0.79
$ 0.79 x 100
-- x --
$ 0.76 - $ 0.80
$ 0.73 - $ 12.88
105,895
na
20.13M
$ -0.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-20-2024 03-31-2024 10-Q
2 04-16-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 07-02-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nkgen-biotech-presents-new-snk01-biomarker-data-at-the-2024-aaic-held-on-july-30-2024

SNK01, a cryopreserved autologous non-genetically modified NK cell product, is able to effectively reduce α-synuclein (α-syn) p...

 why-nkgen-biotech-nkgn-stock-is-skyrocketing

NKGen Biotech shares are trading higher by 32.5% Thursday morning. The company announced it will present new SNK01 biomarker da...

Core News & Articles
Market-Moving News for July 18th
07/18/2024 12:28:09

NKGN: 88% | NKGen Biotech Will Present New Biomarker Data On SNK01 In Alzheimer's Disease During A Poster Presentation At T...

 nkgen-biotech-will-present-new-biomarker-data-on-snk01-in-alzheimers-disease-during-a-poster-presentation-at-the-upcoming-alzheimers-association-international-conference-from-july-28--august-1

NKGen will present data on SNK01's ability to reduce α-synuclein in Alzheimer's patients, which is significant given th...

 why-nkgen-biotech-stock-is-moving-higher-monday

NKGen Biotech shares are trading higher Monday after the company's SNK01 NK Cell Therapy was cleared to begin a Phase 2 tri...

Core News & Articles
Market-Moving News for May 20th
05/20/2024 12:37:59

PTCT: 27% | PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation NKGN: 81% | NK...

Core News & Articles
Market-Moving News for April 29th
04/29/2024 12:46:23

TSLA: 14% | Tesla shares are trading higher on reports the company will partner with Baidu for mapping and navigation for Full ...

 nkgen-biotech-announces-fda-clearance-of-ind-application-for-snk01-nk-cell-therapy-in-parkinsons-disease

NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION